REporting recommendations for tumor MARKer prognostic studies (REMARK) - PubMed (original) (raw)
. 2006 Nov;100(2):229-35.
doi: 10.1007/s10549-006-9242-8. Epub 2006 Aug 24.
Affiliations
- PMID: 16932852
- DOI: 10.1007/s10549-006-9242-8
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M McShane et al. Breast Cancer Res Treat. 2006 Nov.
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, pre-planned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Similar articles
- Reporting recommendations for tumor marker prognostic studies (REMARK).
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. McShane LM, et al. J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4. doi: 10.1093/jnci/dji237. J Natl Cancer Inst. 2005. PMID: 16106022 - REporting recommendations for tumor MARKer prognostic studies (REMARK).
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. McShane LM, et al. Nat Clin Pract Oncol. 2005 Aug;2(8):416-22. Nat Clin Pract Oncol. 2005. PMID: 16130938 - Reporting recommendations for tumor marker prognostic studies (remark).
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. McShane LM, et al. Exp Oncol. 2006 Jun;28(2):99-105. Exp Oncol. 2006. PMID: 16837898 - How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.
Ransohoff DF. Ransohoff DF. J Clin Epidemiol. 2007 Dec;60(12):1205-19. doi: 10.1016/j.jclinepi.2007.04.020. Epub 2007 Sep 24. J Clin Epidemiol. 2007. PMID: 17998073 Review. - Primer: an evidence-based approach to prognostic markers.
Altman DG, Riley RD. Altman DG, et al. Nat Clin Pract Oncol. 2005 Sep;2(9):466-72. doi: 10.1038/ncponc0287. Nat Clin Pract Oncol. 2005. PMID: 16265015 Review.
Cited by
- Association of the Genetic Diversity of Killer Cell Immunoglobulin-like Receptor Genes and HLA-C Ligand in Saudi Women With Thyroid Cancer.
Altalhi RA, Aljuaimlani A, Alswayyed M, Arafah M, Tashkandy Y, Almutairi BO, Mansour L, Alomar SY. Altalhi RA, et al. Cancer Control. 2024 Jan-Dec;31:10732748241274495. doi: 10.1177/10732748241274495. Cancer Control. 2024. PMID: 39365900 Free PMC article. - Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study.
Esin E, Yildirim HC, Oksuzoglu B, Markoc F, Guntekin S, Bilgetekin I, Yildiz F, Yukruk F, Demirci U, Cetin-Atalay R. Esin E, et al. J Clin Med. 2024 Sep 9;13(17):5328. doi: 10.3390/jcm13175328. J Clin Med. 2024. PMID: 39274541 Free PMC article. - Machine-Learning-Based Identification of Key Feature RNA-Signature Linked to Diagnosis of Hepatocellular Carcinoma.
Matboli M, Diab GI, Saad M, Khaled A, Roushdy M, Ali M, ELsawi HA, Aboughaleb IH. Matboli M, et al. J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101456. doi: 10.1016/j.jceh.2024.101456. Epub 2024 Jun 14. J Clin Exp Hepatol. 2024. PMID: 39055616 - Prognostic significance of the neutrophil to lymphocyte ratio in locally advanced breast cancer.
Alshamsan B, Elshenawy MA, Aseafan M, Fahmy N, Badran A, Elhassan T, Alsayed A, Suleman K, Al-Tweigeri T. Alshamsan B, et al. Oncol Lett. 2024 Jul 11;28(3):429. doi: 10.3892/ol.2024.14562. eCollection 2024 Sep. Oncol Lett. 2024. PMID: 39049989 Free PMC article. - Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
Garcia-Torralba E, Pérez Ramos M, Ivars Rubio A, Navarro Manzano E, Blaya Boluda N, Lloret Gil M, Aller A, de la Morena Barrio P, García Garre E, Martínez Díaz F, García Molina F, Chaves Benito A, García-Martínez E, Ayala de la Peña F. Garcia-Torralba E, et al. Breast Cancer Res Treat. 2024 Jun;205(3):475-485. doi: 10.1007/s10549-024-07286-x. Epub 2024 Mar 7. Breast Cancer Res Treat. 2024. PMID: 38453782 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials